Literature DB >> 17580812

Hypothyroidism following hemithyroidectomy for benign nontoxic thyroid disease.

Kristin A Seiberling1, Jose C Dutra, Sanija Bajaramovic.   

Abstract

Hypothyroidism following hemithyroidectomy for benign nontoxic thyroid disease is an underappreciated phenomenon. Up until recently, it was common practice for physicians to place post-hemithyroidectomy patients on thyroid suppression therapy during the immediate postoperative period. That practice began to fall out of favor as a result of two developments: (1) the publication of data that put into question the efficacy of levothyroxine therapy for preventing recurrent disease or thyroid growth and (2) a heightened awareness of the morbidity associated with levothyroxine. We conducted a retrospective chart-review study of 58 patients with benign nontoxic thyroid disease who had undergone hemithyroidectomy from 1994 through 2003 at one institution. Of these 58 patients, 14 (24.1%) had become hypothyroid after surgery, including 7 who had been so diagnosed 1 month postoperatively and 6 at 2 months. The remaining 44 patients were euthyroid. The mean preoperative serum thyroid-stimulating hormone (TSH) levels in the hypothyroid and the euthyroid groups were 2.39 and 1.07 microlU/ml, respectively-a statistically significant difference (p < 0.0001). A tissue diagnosis consistent with chronic inflammation (lymphocytic thyroiditis or Hashimoto's thyroiditis) was found in 50.0% of the hypothyroid patients, compared with only 6.8% of the euthyroid patients-again, a significant difference (p < 0.001). No significant difference was seen between the two grqups with respect to age, sex, or the weight of the resected gland. We conclude that hypothyroidism after hemithyroidectomy is not an uncommon occurrence. Apparent risk factors include a high mean preoperative serum TSH level and tissue pathology consistent with chronic inflammation. It may be wise to follow patients with these identifiable risk factors more closely during the postoperative period; monitoring should include scheduled serial serum TSH draws.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17580812

Source DB:  PubMed          Journal:  Ear Nose Throat J        ISSN: 0145-5613            Impact factor:   1.697


  7 in total

1.  Risk factors for hypothyroidism and thyroid hormone replacement after hemithyroidectomy in papillary thyroid carcinoma.

Authors:  Song Jae Lee; Chang Myeon Song; Yong Bae Ji; Yun Young Choi; Young Seok Sohn; Jung Hwan Park; Dong Sun Kim; Kyung Tae
Journal:  Langenbecks Arch Surg       Date:  2021-05-10       Impact factor: 3.445

Review 2.  Hormone replacement after thyroid and parathyroid surgery.

Authors:  Andreas Schäffler
Journal:  Dtsch Arztebl Int       Date:  2010-11-26       Impact factor: 5.594

3.  Thyroid hormone replacement after thyroid lobectomy.

Authors:  Samantha J Stoll; Susan C Pitt; Jing Liu; Sarah Schaefer; Rebecca S Sippel; Herbert Chen
Journal:  Surgery       Date:  2009-10       Impact factor: 3.982

4.  Prediction of hypothyroidism after hemithyroidectomy: a biochemical and pathological analysis.

Authors:  Yoon Woo Koh; Seung Won Lee; Eun Chang Choi; Jong Dae Lee; Ji Oh Mok; Hee Kyung Kim; Eun Seok Koh; Jae Yong Lee; Shi Chan Kim
Journal:  Eur Arch Otorhinolaryngol       Date:  2007-11-03       Impact factor: 2.503

5.  Hypothyroidism after hemithyroidectomy.

Authors:  Meena Said; Vicki Chiu; Philip I Haigh
Journal:  World J Surg       Date:  2013-12       Impact factor: 3.352

6.  Is it possible to predict hypothyroidism after thyroid lobectomy through thyrotropin, thyroglobulin, anti-thyroglobulin, and anti-microsomal antibody?

Authors:  Jin Seong Cho; Sun Hyoung Shin; Young Ju Song; Hee Kyung Kim; Min Ho Park; Jung Han Yoon; Young Jong Jegal
Journal:  J Korean Surg Soc       Date:  2011-11-25

7.  Management of Subclinical and Overt Hypothyroidism Following Hemithyroidectomy in Children and Adolescents: A Pilot Study.

Authors:  Jiarui Chen; Shule Hou; Xiaoyan Li; Jun Yang
Journal:  Front Pediatr       Date:  2019-09-27       Impact factor: 3.418

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.